4,655 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by Riverbend Wealth Management LLC

Riverbend Wealth Management LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 4,655 shares of the company's stock, valued at approximately $401,000.

Other institutional investors also recently bought and sold shares of the company. Clare Market Investments LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $1,250,000. Independent Advisor Alliance increased its holdings in shares of Novo Nordisk A/S by 1.5% during the 4th quarter. Independent Advisor Alliance now owns 72,642 shares of the company's stock valued at $6,249,000 after purchasing an additional 1,108 shares in the last quarter. Johnson Investment Counsel Inc. increased its holdings in shares of Novo Nordisk A/S by 10.1% during the 4th quarter. Johnson Investment Counsel Inc. now owns 17,607 shares of the company's stock valued at $1,515,000 after purchasing an additional 1,617 shares in the last quarter. Gallagher Capital Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $1,315,000. Finally, Daiwa Securities Group Inc. increased its holdings in shares of Novo Nordisk A/S by 3,688.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 8,790 shares of the company's stock valued at $756,000 after purchasing an additional 8,558 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

NVO traded down $0.82 on Tuesday, hitting $78.14. 7,426,424 shares of the company's stock were exchanged, compared to its average volume of 5,357,347. The firm has a 50-day moving average price of $84.61 and a 200-day moving average price of $104.04. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a market cap of $350.63 billion, a price-to-earnings ratio of 23.75, a P/E/G ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a fifty-two week low of $77.02 and a fifty-two week high of $148.15.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a $0.7874 dividend. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S's payout ratio is 47.72%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on NVO shares. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Sunday, December 29th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.